Medibank share price sell-off 'excessive': expert

Down 20% since the cyberattack, is it time to buy Medibank shares?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Medibank share price went up with most other ASX shares on Friday but remains 20% down since the cyberattack
  • One fund manager says the sell-off has been overdone 
  • Brokerage platform Stake says customers have been buying up big on Medibank shares 

Medibank Private Ltd (ASX: MPL) shares were lifted by broader market momentum on Friday after the United States reported a softer-than-expected inflation number for October.

The Medibank share price finished the session on Friday up 1.79% to $2.84. The S&P/ASX 200 Index (ASX: XJO) finished the day up 2.79% to 7,158 points.

But Friday's surge is likely little comfort to Medibank shareholders. They've seen their investments smashed by almost 20% following news of the cyberattack.

The saga got worse during the week with the cyber thieves publishing a sample of the data on the dark web.

The data includes names, birth dates, contact information, Medicare numbers, and in some cases, individual customer healthcare information.

One fundie says the market has overreacted. Let's hear what he has to say.

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.

Image source: Getty Images

Is Medibank a buy?

Martin Conlon, head of Australian equities at Schroders, says cybercrime is "likely to be an ongoing risk for all organisations".

Conlon says:

We believe the scale of the share price reaction in the case of Medibank Private is likely to be excessive.

More broadly, we question whether many companies are accurately assessing the payoff for many technology investments. The cost savings, customer insights and supposed business efficiencies are nearly always highlighted by management in justifying spend.

The increasing reliance of many companies on external providers, vulnerability to price gouging and increasing business complexity receive less attention.

As my colleague Tony reported this week, QV Equities pounced on Medibank shares during the sell-off.

The company is "using the volatility" of today's market to buy undervalued shares with "strong competitive advantage and recurring earnings".

In a note to clients, QV Equities said:

We used the recent volatility to increase our holdings in high-quality companies at attractive prices including Lottery Corporation Ltd (ASX: TLC) and APA Group (ASX: APA).

We also took the opportunity to increase our holding in Medibank Private after its share price fell heavily after a well-publicised cyber-attack on its client database.

ASX investors take advantage of Medicare share price fall

Analyst Eliot Hastie from Australian brokerage platform Stake says their clients have been buying up big on Medibank shares.

As my colleague Bernd reports, Hastie said:

Stake customers have seen this as a buying opportunity, with a 1,426% increase in buys last month, suggesting that many are still positive about Medibank's long-term outlook.

In fact, Medibank saw the biggest change from sales to buys of all Australian stocks in October when compared to September.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended APA Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

How does Bell Potter rate these ASX healthcare stocks?

Let's see what the broker is saying about these shares.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Healthcare Shares

Why is this ASX 300 stock rocketing 17% today?

Let's see what is getting investors excited today.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Should you buy CSL and Pro Medicus shares today?

Both stocks have been hammered, but brokers see upside of 60% or more.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech company has piled on more than 25% after a big announcement

A deal around a novel drug delivery compound has investors interested.

Read more »

A young man stands facing the camera and scratching his head with the other hand held upwards wondering if he should buy Whitehaven Coal shares
Healthcare Shares

Telix shares drop despite promising US FDA update

Market weakness is overshadowing this news.

Read more »

Stressed, unhappy and tired scientist with a headache working on a computer in a lab. Worried, anxious and frustrated pathologist, researcher and doctor struggling with burnout, tension and strain.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this ASX share deliver healthy returns or will things get worse?

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Game over? ASX biotech stock crashes 90% on big bad news

Is it game over for this stock? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Should you buy low on these ASX healthcare stocks?

These two stocks could be poised for a bounce back.

Read more »